



COPY OF PAPERS
ORIGINALLY FILED

Patent
Attorney Docket No: ANP-00114.P.5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Pakula et al.

Application Number: 09/904,186

Filed: July 12, 2001

For: SCREENING METHOD FOR
IDENTIFYING LIGANDS FOR
TARGET PROTEINS

Examiner: P. Ponnaluri

Group Art Unit: 1627

#10 (RE)
SUS
9-18-02

Assistant Commissioner for Patents
Washington D.C., 20231

Sir,

**POWER OF ATTORNEY FROM ASSIGNEE
AND REVOCATION OF PRIOR POWERS**


The undersigned, as a representative of the assignee of the above-identified patent application as shown by the attached

- [x] copy of the filing receipt
- [x] copy of the assignments from US Application Ser. No. 08/263,923, a parent application, which assigned all patents, divisions, reissues, continuations, and extensions of that application to assignee.
- [x] copy of the Notice of Recordation of Assignment Document for change of name from Scriptech Pharmaceuticals, Inc. To ScripGen Pharmaceuticals, Inc.
- [x] copy of the Notice of Recordation of Assignment Document for change of name from Scriptgen Pharmaceuticals, Inc. to Anadys Pharmaceuticals, Inc.

hereby revokes all previous powers and appoints David R. Preston & Associates, A.P.C., 12625 High Bluff Drive, Suite 205, San Diego, California 92130, telephone number 858.724.0375 and facsimile number 858.724.0384, **Customer Number 24232** (to whom all communications about this application are to be directed), and the below named persons (of the same address), collectively and individually our attorney and agent, to prosecute this patent application and to transact all business in the United States Patent and Trademark Office connected therewith and with the resulting patent:

David R. Preston Reg. No. 38,710
Elizabeth A. Orr Reg. No. 45,937
Thomas D. Foster Reg. No. 44,686

FOR ANADYS PHARMACEUTICALS, INC.



8-28-02

Date

KLEANTHIS G. XANTHOPOULOS
Name

PRESIDENT + CEO
Title



COPY OF PAPERS
ORIGINALLY FILED

Page 1 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/904,186	07/12/2001	1642	2184	0342/19045- US5	11	65	9

CONFIRMATION NO. 2874

UPDATED FILING RECEIPT



OC000000007179918

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

Date Mailed: 12/11/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Andrew Pakula, Lexington, MA;
James Bowie, Culver City, CA;

Assignment For Published Patent Application

Anadys Pharmaceuticals, Inc.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 08/978,381 11/25/1997 ABN
WHICH IS A CON OF 08/547,889 10/25/1995 ABN
WHICH IS A CIP OF 08/263,923 06/21/1994 PAT 5,679,582
WHICH IS A CIP OF 08/080,829 06/21/1993 ABN

Foreign Applications

If Required, Foreign Filing License Granted 08/02/2001

Projected Publication Date: 03/21/2002

Non-Publication Request: No

Early Publication Request: No

Title

Screening method for identifying ligands for target proteins

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

ASSIGNMENT

I, James U. Bowie, a citizen of the United States of America, residing at 4243 Lebourget Avenue, Culver City, CA 90232

(hereafter called "ASSIGNOR") in consideration of the sum of One Dollar (\$1.00) or the equivalent thereof, and other good and valuable consideration paid to me by **SCRIPTECH PHARMACEUTICALS, INC.**, a corporation organized and existing under the laws of the State of Delaware, located at 200 Boston Avenue, Suite 3000, Medford, MA 02155, (hereafter called the "ASSIGNEE"), do hereby sell and assign to the said ASSIGNEE, its successors and assigns, all of my right, title and interest, in and for the United States of America, in and to the following United States patent application:

U.S. Serial No.: 08/263,923

Filed: June 21, 1994

For: A SCREENING METHOD FOR IDENTIFYING LIGANDS FOR
TARGET PROTEINS

invented by and me and described in the application for United States Letters Patent therefor, and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations, and extensions thereof, the said interest being my entire ownership interest in said Letters Patent when granted, to be held and enjoyed by said ASSIGNEE, its successors, assigns or other legal representatives, to the full end of the term of which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR if this assignment and sale had not been made;

And ASSIGNOR hereby agrees to sign and execute any further documents or instruments which may be necessary, lawful, and proper in the prosecution of said above named application or in the preparation and prosecution of any continuing, continuation-in-part, substitute, divisional, renewal, or reissue applications or in any amendment, extension, or interference proceedings, or otherwise to secure the title thereto in said ASSIGNEE;

And the said ASSIGNOR hereby authorizes and requests that Commissioner of Patents and Trademarks to issue said Letters Patent to said ASSIGNEE.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on: 8/22/94
(Date)

James U. Bowie
JAMES U. BOWIE, Inventor

ASSIGNMENT

I, Andrew Pakula, a citizen of the United States of America, residing at 26 Normady Road, Lexington, MA 02173.

(hereafter called "ASSIGNORS") in consideration of the sum of One Dollar (\$1.00) or the equivalent thereof, and other good and valuable consideration paid to me by **SCRIPTECH PHARMACEUTICAL, INC.**, a corporation organized and existing under the laws of the State of *Delaware*, located at *200 Boston Avenue, Suite 3000, Medford, MA 02155*, (hereafter called the "ASSIGNEE"), do hereby sell and assign to the said ASSIGNEE, its successors and assigns, all of my right, title and interest, in and for the United States of America, in and to the following United States patent application:

U.S. Serial No.: 08/263,923

Filed: June 21, 1994

For: *A Screening Meethod For Identifying Ligands For Target Proteins*

invented by and me and described in the application for United States Letters Patent therefor, and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations, and extensions thereof, the said interest being my entire ownership interest in said Letters Patent when granted, to be held and enjoyed by said ASSIGNEE, its successors, assigns or other legal representatives, to the full end of the term of which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by said ASSIGNOR if this assignment and sale had not been made;

And ASSIGNORS hereby agrees to sign and execute any further documents or instruments which may be necessary, lawful, and proper in the prosecution of said above named application or in the preparation and prosecution of any continuing, continuation-in-part, substitute, divisional, renewal, or reissue applications or in any amendment, extension, or interference proceedings, or otherwise to secure the title thereto in said ASSIGNEE;


And the said ASSIGNORS hereby authorizes and requests that Commissioner of Patents and Trademarks to issue said Letters Patent to said ASSIGNEE.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on: _____

8/12/94

(Date)


Andrew Pakula, Inventor



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

MARCH 17, 1997

PTAS



100336790A

DARBY & DARBY P.C.
S. PETER LUDWIG, ESQ.
805 THIRD AVENUE, 27TH FLOOR
NEW YORK, NEW YORK 10022-7513

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 12/05/1996

REEL/FRAME: 8297/0854
NUMBER OF PAGES: 3

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

SCRIPTTECH PHARMACEUTICALS, INC.

DOC DATE: 11/18/1994

ASSIGNEE:

SCRIPTGEN PHARMACEUTICALS, INC.
200 BOSTON AVENUE, SUITE 300
MEDFORD, MASSACHUSETTS 02155

SERIAL NUMBER: 08263923

FILING DATE: 06/21/1994

PATENT NUMBER:

ISSUE DATE:

SEDLEY PYNE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

NOVEMBER 20, 2000

PTAS

DARBY & DARBY P.C.
S. PETER LUDWIG
805 THIRD AVENUE, 27TH FLOOR
NEW YORK, NY 10022-7513



UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 11/17/2000

REEL/FRAME: 011111/0228
NUMBER OF PAGES: 3

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

SCRIPTGEN PHARMACEUTICALS, INC.

DOC DATE: 06/27/2000

ASSIGNEE:

INADYS PHARMACEUTICALS, INC.
610 LINCOLN STREET
WALTHAM, MASSACHUSETTS 02451

SERIAL NUMBER: 08547889
PATENT NUMBER:

FILING DATE: 10/25/1995
ISSUE DATE:

SERIAL NUMBER: 08978381
PATENT NUMBER:

FILING DATE: 11/25/1997
ISSUE DATE:

SERIAL NUMBER: 08709342
PATENT NUMBER:

FILING DATE: 09/06/1996
ISSUE DATE:

SERIAL NUMBER: 08351659
PATENT NUMBER: 6051373

FILING DATE: 12/07/1994
ISSUE DATE: 04/18/2000

SERIAL NUMBER: 08709343
PATENT NUMBER: 5942547

SERIAL NUMBER: 09629809
PATENT NUMBER:

SERIAL NUMBER: 08822323
PATENT NUMBER: 5986111

SERIAL NUMBER: 09002541
PATENT NUMBER: 6022983

SERIAL NUMBER: 09397765
PATENT NUMBER:

SERIAL NUMBER: 09397764
PATENT NUMBER:

SERIAL NUMBER: 09574134
PATENT NUMBER:

SERIAL NUMBER: 09180827
PATENT NUMBER:

SERIAL NUMBER: 08626309
PATENT NUMBER:

SERIAL NUMBER: 09204841
PATENT NUMBER:

SERIAL NUMBER: 09082920
PATENT NUMBER:

SERIAL NUMBER: 09060449
PATENT NUMBER:

SERIAL NUMBER: 09153202
PATENT NUMBER:

SERIAL NUMBER: 09404066
PATENT NUMBER:

SERIAL NUMBER: 09496919
PATENT NUMBER:

SERIAL NUMBER: 09413409
PATENT NUMBER:

SERIAL NUMBER: 09413405
PATENT NUMBER:

SERIAL NUMBER: 09501753
PATENT NUMBER:

FILING DATE: 09/06/1996
ISSUE DATE: 08/24/1999

FILING DATE: 07/31/2000
ISSUE DATE:

FILING DATE: 03/21/1997
ISSUE DATE: 11/16/1999

FILING DATE: 01/02/1998
ISSUE DATE: 02/08/2000

FILING DATE: 09/15/1999
ISSUE DATE:

FILING DATE: 09/15/1999
ISSUE DATE:

FILING DATE: 05/18/2000
ISSUE DATE:

FILING DATE: 01/26/1999
ISSUE DATE:

FILING DATE: 04/01/1996
ISSUE DATE:

FILING DATE: 12/03/1998
ISSUE DATE:

FILING DATE: 01/16/1998
ISSUE DATE:

FILING DATE: 03/05/1998
ISSUE DATE:

FILING DATE: 09/15/1998
ISSUE DATE:

FILING DATE: 09/23/1999
ISSUE DATE:

FILING DATE: 02/02/2000
ISSUE DATE:

FILING DATE: 10/06/1999
ISSUE DATE:

FILING DATE: 10/06/1999
ISSUE DATE:

FILING DATE: 02/10/2000
ISSUE DATE:

SERIAL NUMBER: 09229703
PATENT NUMBER:

FILING DATE: 01/13/1999
ISSUE DATE:

SERIAL NUMBER: 09314864
PATENT NUMBER:

FILING DATE: 05/19/1999
ISSUE DATE:

SERIAL NUMBER: 09495066
PATENT NUMBER:

FILING DATE: 01/31/2000
ISSUE DATE:

SERIAL NUMBER: 08263923
PATENT NUMBER: 5679582

FILING DATE: 06/21/1994
ISSUE DATE: 10/21/1997

SERIAL NUMBER: 08407945
PATENT NUMBER: 5585277

FILING DATE: 03/21/1995
ISSUE DATE: 12/17/1996

SERIAL NUMBER: 08308818
PATENT NUMBER: 5847077

FILING DATE: 09/19/1994
ISSUE DATE: 12/08/1998

SERIAL NUMBER: 08475883
PATENT NUMBER: 5668165

FILING DATE: 06/07/1995
ISSUE DATE: 09/16/1997

SERIAL NUMBER: 08915515
PATENT NUMBER: 6020488

FILING DATE: 08/13/1997
ISSUE DATE: 02/01/2000

SERIAL NUMBER: 09273964
PATENT NUMBER: 6140361

FILING DATE: 03/22/1999
ISSUE DATE: 10/31/2000

SERIAL NUMBER: 08713724
PATENT NUMBER: 5760063

FILING DATE: 09/13/1996
ISSUE DATE: 06/02/1998

SERIAL NUMBER: 09370535
PATENT NUMBER: 6127551

FILING DATE: 08/09/1999
ISSUE DATE: 10/03/2000

SERIAL NUMBER: 09370533
PATENT NUMBER: 6090953

FILING DATE: 08/09/1999
ISSUE DATE: 02/12/2000

SERIAL NUMBER: 08625377
PATENT NUMBER: 5863762

FILING DATE: 04/01/1996
ISSUE DATE: 01/26/1999

SERIAL NUMBER: 09138024
PATENT NUMBER: 6004779

FILING DATE: 08/21/1998
ISSUE DATE: 12/21/1999

SEDLEY PYNE, PARALEGAL
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

1627




TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number:	09/904,186
		Filing Date:	July 12, 2001
		First Named Inventor:	Pakula
		Group Art Unit:	1627
		Examiner:	P. Ponnaluri
Total Pages in This Submission:	10	Attorney Docket Number:	ANP-00114.P.5


RECEIVED

SEP 11 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal, Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits / Declarations(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Requests	<input checked="" type="checkbox"/> Power of Attorney and Revocation of Power of Attorney	<input type="checkbox"/> Additional enclosures, identified below: Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts / Incomplete Application	Remarks:	
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual Name	David R. Preston
Signature	 Reg. No. 38,710
Date	September 4, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date.	
Date:	9/4/02
Typed or printed name:	David R. Preston
Signature	 Date: 9/4/02



RECEIVED

FEE TRANSMITTAL		Complete if Known	
Patent fees are subject to annual revision on October 1. These are the fees effective October 1, 1997. Small Entity payments <u>must</u> be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12. See 37 C.F.R. §§ 1.27 and 1.28.		Application Number:	09/904,186
		Filing Date:	July 12, 2001
		First Named Inventor:	Pakula
		Group / Art Unit:	1627
Total Amount of Payment	\$ 0.00	Docket Number:	ANP-00114.P.5

SEP 11 2002
TECH CENTER 1600/2900

METHOD OF PAYMENT
1. <input type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any over payments to: Deposit Account Number: <input type="checkbox"/> Deposit Account Name: <input type="checkbox"/> <input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17 <input type="checkbox"/> Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.
2. <input type="checkbox"/> Payment Enclosed <input type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other

FEE CALCULATION						
1. BASIC FILING FEE						
	Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
	101	790	201	395	Utility Filing Fee	\$
	106	330	206	165	Design Filing Fee	\$
	107	540	207	270	Plant Filing Fee	\$
	108	790	208	395	Reissue Filing Fee	\$
	114	150	214	75	Provisional Filing Fee	\$
SUBTOTAL (1)						\$ 0.00

2. EXTRA CLAIM FEES

				Extra Claims		Fee From Below		Fee Paid
Total Claims	[]	-20 **	Equals	[]	Times	[]	Equals	\$
Independent Claims	[]	-3 **	Equals	[]	Times	[]	Equals	\$
Subtotal (2)								\$ 0.00

** or number previously paid, if greater, For Reissues, see below


	Large Entity		Small Entity		Fee Description
	Fee Code	Fee (\$)	Fee Code	Fee (\$)	
	103	22	203	11	Claims in excess of 20
	102	82	202	41	Independent claims in excess of 3
	104	270	204	135	Multiple dependent claim, if not paid
	109	82	209	41	** Reissue independent claims over original patent
	110	22	210	11	** Reissue claims in excess of 20 and over original patent

3. ADDITIONAL FEES					
Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	\$
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	\$
139	130	139	130	Non-English specification	\$
147	2,520	147	2,520	For filing a request for reexamination	\$
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	\$
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	\$
115	110	215	55	Extension for reply within first month	\$
116	400	216	200	Extension for reply within second month	\$
117	950	217	475	Extension for reply within third month	\$
118	1,510	218	755	Extension for reply within fourth month	\$
128	2,060	228	1,030	Extension for reply within fifth month	\$
119	310	219	155	Notice of Appeal	\$
120	310	220	155	Filing a brief in support of an appeal	\$
121	270	221	135	Request for oral hearing	\$
138	1,510	138	1,510	Petition to institute a public use proceeding	\$
140	110	240	55	Petition or revive - unavoidable	\$
141	1,320	241	660	Petition or revive - unintentional	\$
142	1,320	242	660	Utility issue fee (or reissue)	\$
143	450	243	225	Design issue fee	\$
144	670	244	335	Plant issue fee	\$
122	130	122	130	Petitions to the Commissioner	\$
123	50	123	50	Petitions related to provisional applications	\$
126	240	126	240	Submission of Information Disclosure Statement	\$
581	40	581	40	Recording each patent assignment per property	\$
146	790	246	395	Filing a submission after final rejection (37 C.F.R. 1.129(a))	\$
149	790	249	395	For each additional invention to be examined (37 CFR 1.129(b))	\$
Other fee (specify)					\$
* Reduced by Basic Filing Fee Paid				Subtotal (3)	\$ 0.00

Fee Transmittal
Corresponding to PTO/SB/17

4. SUMMATION OF FEES

SUBTOTAL (1)	\$ 0.00
SUBTOTAL (2)	\$ 0.00
SUBTOTAL (3)	\$ 0.00
TOTAL FEES	\$ 0.00

SUBMITTED BY			Complete (If Applicable)	
Typed or Printed Name	David R. Preston		Registration Number:	38,710
Signature		Date: 9/4/02	Deposit Account User ID Number	501321